Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) Equity Average (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Equity Average for 10 consecutive years, with $4.2 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 25.45% to $4.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 billion through Dec 2025, up 25.45% year-over-year, with the annual reading at $3.8 billion for FY2025, 11.99% up from the prior year.
  • Equity Average for Q4 2025 was $4.2 billion at BeOne Medicines, up from $3.9 billion in the prior quarter.
  • The five-year high for Equity Average was $6.0 billion in Q1 2022, with the low at $3.4 billion in Q2 2024.
  • Average Equity Average over 5 years is $4.1 billion, with a median of $3.9 billion recorded in 2021.
  • The sharpest move saw Equity Average soared 107.77% in 2021, then dropped 28.27% in 2023.
  • Over 5 years, Equity Average stood at $4.7 billion in 2021, then fell by 4.75% to $4.5 billion in 2022, then decreased by 19.23% to $3.7 billion in 2023, then decreased by 7.29% to $3.4 billion in 2024, then increased by 25.45% to $4.2 billion in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $4.2 billion, $3.9 billion, and $3.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.